// App-Quantinova.ai

4310 : Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Researchers

Presenter

  • Daniel C. Danila

Principal Investigators

  • Howard I. Scher

  • Edith Szafer-Glusman

  • Ron Firestein

  • Michael Mamounas

  • Mark R. Lackner

  • Omar Kabbarah

  • Amrita Herkal

  • Rebecca Suttmann

  • Martin Fleisher

  • Nicole A. Schreiber

  • Kristen Curtis

  • Houston Gilbert

  • Daniel Maslyar

  • Bernard Fine

Medical Centers

  • Memorial Sloan Kettering, New York, NY

Locations

  • United States

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • STEAP Family Member 1

  • Apparent diffusion coefficient

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved